Recurrent white thrombi formation in hemodialysis tubing: a case report

BMC Nephrology

Kar-Hui Ng²  Hui-Kim Yap²  Mohammed Azar¹  Sudha Ekambaram¹  Isaac Desheng Liu¹  Wee-Song Yeo¹  Kiran P Sathe¹ 

[1] Shaw-NKF-NUH Children’s Kidney Centre, Khoo Teck Puat-National University Children’s Medical Institute, National University Health System, Level 12 NUHS Tower Block, 1E Kent Ridge Road, Singapore 119228, Singapore;Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

关键词: Home;    Hemodialysis;    Blood platelets;    Thrombosis;    Renal dialysis;    Platelet activation;   

Others  :  1113262
DOI  :  10.1186/1471-2369-16-3

 received in 2014-11-13, accepted in 2015-01-05,  发布年份 2015

【 摘 要 】

Background

While the appearance of red clots in the dialyzer is a common phenomenon in every hemodialysis unit, the occurrence of white thrombi in the tubing is relatively rare.

Case presentation

We describe an adolescent male with recurrent white thrombi formation in the hemodialysis tubing. This patient had chronic renal failure from focal segmental glomerulosclerosis, but was no longer nephrotic at the time of the thrombi formation. He had a history of recurrent thrombosis of his vascular access. However, no pro-thrombotic risk factors could be identified. White particulate matter, measuring 1 to 3mm in size, and adherent to the arterial and venous blood tubing lines was found during the rinse back of a hemodialysis session. This was associated with a 60% decrease in his platelet count. Light microscopic examination of the deposits revealed the presence of platelet aggregates. He subsequently developed thrombosis of his arteriovenous graft six hours later. The white thrombi recurred at the next dialysis session, as well as six months later. These episodes occurred regardless of the type of dialysis machine or tubing, and appeared to resolve with an increase in heparin dose.

Conclusion

Recurrent white thrombi formation can occur in the hemodialysis tubing of a patient with no identifiable pro-thrombotic factors. The white thrombi may be a harbinger of arteriovenous graft thrombosis and may be prevented by an increase in heparin dose.

【 授权许可】

   
2015 Sathe et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Baccheschi S, Sereni L, De Nitti C, Barbucci R, Tetta C: Blood tubing and cytokine production: effect of sterilization. Ren Fail 2001, 23(3–4):411.
• [2]Joannidis M, Oudemans-van Straaten HM: Clinical review: Patency of the circuit in continuous renal replacement therapy. Crit Care 2007, 11(4):218. BioMed Central Full Text
• [3]Daugirdas JT, Bernardo AA: Hemodialysis effect on platelet count and function and hemodialysis-associated thrombocytopenia. Kidney Int 2012, 82(2):147-157.
• [4]Hakim R, Schafer A: Hemodialysis-associated platelet activation and thrombocytopenia. Am J Med 1985, 78(4):575.
• [5]De Prada L, Lee J, Gillespie A, Benjamin J: Thrombocytopenia associated with one type of polysulfone hemodialysis membrane: A report of 5 cases. Am J Kidney Dis 2013, 61(1):131-133.
• [6]Kiaii M, Djurdjev O, Farah M, Levin A, Jung B, MacRae J: Use of electron-beam sterilized hemodialysis membranes and risk of thrombocytopenia. JAMA 2011, 306(15):1679.
• [7]Allison S: Dialysis: Dialyzer sterilization method linked to thrombocytopenia. Nat Rev Nephrol 2011, 7(12):676.
• [8]Sirolli V, Ballone E, Di Stante S, Amoroso L, Bonomini M: Cell activation and cellular-cellular interactions during hemodialysis: effect of dialyzer membrane. Int J Artif Organs 2002, 25(6):529.
• [9]Watnick S, Stooksbury M, Winter R, Riscoe M, Cohen DM: White thrombus formation in blood tubing lines in a chronic hemodialysis unit. Clin J Am Soc Nephrol 2008, 3(2):382.
• [10]Sagripanti A, Cupisti A, Baicchi U, Ferdeghini M, Morelli E, Barsotti G: Plasma parameters of the prothrombotic state in chronic uremia. Nephron 1993, 63(3):273-278.
• [11]Gordge MP, Leaker BR, Rylance PB, Neild GH: Haemostatic activation and proteinuria as factors in the progression of chronic renal failure. Nephrol Dial Transplant 1991, 6(1):21-26.
• [12]Martinovic Z, Basic-Jukic N, Pavlovic DB, Kes P: Importance of platelet aggregation in patients with end-stage renal disease. Acta Clin Croat 2013, 52(4):472-477.
• [13]Salvati F, Liani M: Role of platelet surface receptor abnormalities in the bleeding and thrombotic diathesis of uremic patients on hemodialysis and peritoneal dialysis. Int J Artif Organs 2001, 24(3):131-135.
• [14]Serradell M, Diaz-Ricart M, Cases A, Zurbano MJ, Aznar-Salatti J, Lopez-Pedret J, Ordinas A, Escolar G: Uremic medium disturbs the hemostatic balance of cultured human endothelial cells. Thromb Haemost 2001, 86(4):1099-1105.
• [15]Chitalia VC, Shivanna S, Martorell J, Balcells M, Bosch I, Kolandaivelu K, Edelman ER: Uremic serum and solutes increase post-vascular interventional thrombotic risk through altered stability of smooth muscle cell tissue factor. Circulation 2013, 127(3):365-376.
• [16]Farid FA, Faheem MS, Heshmat NM, Shaheen KY, Saad SS: Study of the homocysteine status in children with chronic renal failure. Am J Nephrol 2004, 24(3):289-295.
• [17]Fadel FI, Elshamaa MF, Essam RG, Elghoroury EA, El-Saeed GS, El-Toukhy SE, Ibrahim MH: Some amino acids levels: glutamine, glutamate, and homocysteine, in plasma of children with chronic kidney disease. Int J Biomed Sci 2014, 10(1):36-42.
• [18]Wu CC, Zheng CM, Lin YF, Lo L, Liao MT, Lu KC: Role of homocysteine in end-stage renal disease. Clin Biochem 2012, 45(16–17):1286-1294.
• [19]Bostom AG, Lathrop L: Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997, 52(1):10-20.
• [20]Van Campenhout A, Moran CS, Parr A, Clancy P, Rush C, Jakubowski H, Golledge J: Role of homocysteine in aortic calcification and osteogenic cell differentiation. Atherosclerosis 2009, 202(2):557-566.
• [21]Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME: Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A 1994, 91(14):6369-6373.
• [22]Cetin O, Bekpinar S, Unlucerci Y, Turkmen A, Bayram C, Ulutin T: Hyperhomocysteinemia in chronic renal failure patients: relation to tissue factor and platelet aggregation. Clin Nephrol 2006, 65(2):97-102.
• [23]Syed S, Reilly R: Heparin-induced thrombocytopenia: a renal perspective. Nat Rev Nephrol 2009, 5(9):501.
• [24]Lim W, Cook DJ, Crowther MA: Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol 2004, 15(12):3192-3206.